Trial intelligence / Profile preview

PK Study of Grammidin Spray vs Lozenges

NCT06859281Phase 1Recruiting

Sponsor
Valenta Pharm
Start
Dec 2024
Primary completion
Dec 2026
Modality
Peptides, Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of gramicidin S in pharyngitis (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 3 more. Started Dec 2024; status: recruiting.

02

Drugs

gramicidin S
03

Conditions

pharyngitis

Beyond the preview

Go deeper on NCT06859281.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06859281.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call